Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients

Clinical trial NCT02324803 · UNKNOWN

Trial details

NCT number: NCT02324803
Sponsor: Southern China Urology Cancer Consortium
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Self Efficacy Adverse Drug Event Carcinoma, Renal Cell

Start date: 2014-07-01
Primary completion: 2015-12-01
Enrollment: 86

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.